Signablok

Science in Focus

SCHOOL platform: Biophysical principles

SCHOOL platform for receptor signaling

SCHOOL concept: Learning from viruses

SCHOOL approach to sepsis, lung cancer, breast and pancreatic cancer, autoimmune diseases and others

Book in Focus

News in Focus

• SignaBlok has been highlighted by Mass High Tech as a top company to watch
  Read more
• SignaBlok targets $2.5M funding to treat lung, breast cancer
  Read more
• SignaBlok aims to condense virus evolution, discover new drug solutions
  Read more
• UMass research focuses on anti-clotting platform
  Read more

Partners

Partner	Product/Project	Type	Year est.
DARPA1	New Therapeutic Approach to Sepsis: Inhibition of TREM-1 Signaling with Transmembrane Peptide Variants	Contract agreement	2012
NHLBI/NIH2	Multifunctional nanoformulations for diagnostic imaging of atherosderosis	Phase I SBIR grant	2012
NCI/NIH3	Development of novel targeted agents in lung cancer	Phase I SBIR grant	2012
UTSMC4	Novel treatment development for cancer cachexia	Collaboration agreement	2012

¹ The Defense Advanced Research Projects Agency (DARPA) is a component of the United States Department of Defense, focused on sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military and civilian use.

² The National Heart, Lung, and Blood Institute (NHLBI) is a component of the National Institutes of Health (NIH), focused on providing global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases.

³ The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH) and the Federal Government's principal agency for cancer research and training.

⁴ The University of Texas Southwestern Medical Center (UTSMC) is one of the leading medical schools and biomedical research institutions in the United States.

We are seeking partnerships and collaborations with granting agencies, disease foundations, and academia through SBIR/STTR projects or other mechanisms, as well as with larger and more established biotech and pharma companies to take products through the animal studies and clinical trials process and/or to license our products.

Type Collaborative R&D, secure strategic alliances, joint ventures, partnerships, licensing deals, etc. Product* GPVI inhibitors TCR inhibitors TREM-1 inhibitors Nanotherapeutics Nanodiagnostics Indication Thrombotic disorders Rheumatoid arthritis, dermatitis, scleroderma Non-small cell lung cancer, breast cancer, sepsis, hemorrhagic shock Breast and lung cancer, infectious diseases, sepsis, atherosclerosis Breast and lung cancer, atherosclerosis Application Systemic and stent coatings Systemic and topical Systemic and topical Systemic nanoparticulate therapeutics and imaging agents Image-guided therapy

 

* GPVI, glycoprotein VI (the major collagen receptor on platelets); TCR, T cell receptor; TREM-1, triggering receptor expressed on myeloid cells-1

- We make a difference in science. You feel the difference in health.